Serina Therapeutics (NYSEAMERICAN:SER) Posts Earnings Results

Serina Therapeutics (NYSEAMERICAN:SER) issued its quarterly earnings results on Thursday. The company reported ($0.31) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.13 million for the quarter.

Serina Therapeutics Stock Performance

NYSEAMERICAN:SER remained flat at $1.41 during trading hours on Friday. 5,055 shares of the company were exchanged, compared to its average volume of 1,345,863. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.65 and a quick ratio of 6.65. The company has a market capitalization of $35.81 million, a price-to-earnings ratio of -0.75 and a beta of 1.29. The firm’s 50-day moving average price is $1.97 and its 200-day moving average price is $2.04. Serina Therapeutics has a one year low of $1.14 and a one year high of $4.26.

Wall Street Analysts Forecast Growth

Separately, BTIG Research reiterated a “buy” rating and issued a $8.00 target price on shares of Serina Therapeutics in a research report on Monday, October 26th. One research analyst has rated the stock with a Buy rating. According to MarketBeat.com, Serina Therapeutics currently has an average rating of “Buy” and a consensus price target of $8.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Serina Therapeutics stock. Ashton Thomas Private Wealth LLC acquired a new position in Serina Therapeutics, Inc. (NYSEAMERICAN:SER) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 88,888 shares of the company’s stock, valued at approximately $178,000. Ashton Thomas Private Wealth LLC owned 0.35% of Serina Therapeutics at the end of the most recent quarter. 12.50% of the stock is currently owned by institutional investors.

Serina Therapeutics Company Profile

Serina Therapeutics is a clinical-stage biopharmaceutical company developing medicines designed to provide longer-lasting and more consistent therapeutic effects. The company uses its proprietary POZ polymer technology to modify existing drug compounds, with the goal of extending their duration of action and potentially improving treatment convenience and tolerability. Serina’s lead program is POZ-apomorphine, also referred to as SER-252, an investigational therapy being developed for patients with advanced Parkinson’s disease.